#shingles vaccine market

[mitalipingale]

The Shingles Vaccine Market in 2023 is US$ 3.99 billion, and is expected to reach US$ 8.63 billion by 2031 at a CAGR of 10.10%.

[industryforecastnews]

Shingles Vaccine Market Size To Reach USD 11.26 Billion By 2030

Shingles Vaccine Market Growth & Trends

The global shingles vaccine market size is expected to reach USD 11.26 billion by 2030, registering a CAGR of 15.34% during the forecast period, according to a new report by Grand View Research, Inc. Increasing incidence of shingles and high awareness regarding shingles in developed countries are contributing to the market growth. According to the CDC, nearly one million cases of shingles are reported each year in the United States. Furthermore, one out of three individuals in the country will develop the disease in their lifetime.

The increasing adoption of vaccines and an increase in the recommendation of vaccination by different government regulatory bodies are expected to drive the market over the forecast period. For instance, in February 2019, the U.K. Joint Committee of Vaccination and Immunization (JCVI) has recommended the use of the recombinant vaccine to prevent shingles in adults aged 60 to 70 years old.

The inclusion of shingles vaccines in national immunization programs of several countries is anticipated to propel the demand for vaccines. For instance, the shingles vaccine is a part of the national immunization program in the U.K. since 2013. The U.K. is the first country in the European region to introduce shingles vaccine in the national immunization program and it costs around USD 130 to the National Health Service (NHS) for each dose of the vaccine. Similarly, other countries such as the U.S., Italy, Australia, and some provinces of Canada and South Korea have also included the vaccine in their immunization program.

Besides, favorable initiatives undertaken by market players and regulatory bodies to increase the awareness among people who are at risk of developing the disease are expected to fuel the market growth over the coming years. For instance, GlaxoSmithKline plc. has launched a campaign to increase vaccination rates among older adults by educating people about the benefits associated with vaccination.

The high efficacy of vaccines is expected to increase the adoption over the forecast period. According to clinical trial results, Shingrix is highly efficient to prevent shingles and postherpetic neuralgia. Two doses of Shingrix are more than 90% effective to prevent the disease in adults aged 50 years and above. Protection stays above 85% for at least the first four years after getting vaccinated.

The availability of vaccines at lower prices, coupled with a high incidence of the disease and high vaccination rate in developed countries, is anticipated to fuel the market growth. The vaccination rate against shingles in the U.K., the U.S., France, Canada, Germany, and South Korea is higher compared to other countries owing to better reimbursement policies and high awareness levels regarding the disease and vaccines. For instance, the U.K. has the highest shingles vaccine uptake with more than 60% vaccination of eligible adults.

Request a free sample copy or view report summary: https://www.grandviewresearch.com/industry-analysis/shingles-vaccine-market-report

Shingles Vaccine Market Report Highlights

By product, Shingrix held the largest share in 2023, owing to the high efficacy of the vaccine as compared to others. Shingrix is also expected to grow at a significant CAGR over the forecast period owing to the increasing recommendations by regulatory bodies to prevent shingles

Based on vaccine type, the recombinant vaccine segment is anticipated to grow at a substantial rate over the forecast period due to the low risk associated with recombinant vaccines

Asia Pacific is projected to witness the fastest growth during the forecast period owing to the high unmet needs and the rising adoption of vaccination programs in the region

North America dominated the market in 2023, due to favorable reimbursement policies and rising initiatives to raise awareness among healthcare professionals and patients.

Shingles Vaccine Market Segmentation

Grand View Research has segmented the global shingles vaccine market based on product, type, end-use, and region:

Shingles Vaccine Product Outlook (Revenue, USD Million, 2018 - 2030)

Shingrix

Zostavax

SKYZoster

Shingles Vaccine Type Outlook (Revenue, USD Million, 2018 - 2030)

Recombinant Vaccine

Live Attenuated Vaccine

Shingles Vaccine End Use Outlook (Revenue, USD Million, 2018 - 2030)

Private Healthcare Settings

Government Healthcare Settings

Shingles Vaccine Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

U.S.

Canada

Mexico

Europe

Germany

UK

France

Italy

Spain

Denmark

Sweden

Norway

Asia Pacific

China

Japan

India

South Korea

Australia

Thailand

Latin America

Brazil

Argentina

Middle East and Africa (MEA)

South Africa

Saudi Arabia

Kuwait

UAE

List of Key Players of Shingles Vaccine Market

GlaxoSmithKline plc.

Merck & Co., Inc.

SK chemicals

Green Cross Corp

Geneone Life Science

Vaccitech

CanSinoBIO

Request a free sample copy or view report summary: https://www.grandviewresearch.com/industry-analysis/shingles-vaccine-market-report

[bishtmeenakshi]

Vaccinating the World: Can the Market Deliver on Its Promise?

Explore the potential of the vaccine market to deliver on its promise of global immunization. Analyze trends, size, and future outlook across various vaccine segments, including pneumococcal, dengue, DNA, typhoid fever, and foot and mouth disease vaccines market.

[lazyscience]

So for my followers who come with a factory-installed uterus I know you're concerned about your health and autonomy. And you well should be

But here's something all of you should be thinking about and planning for no matter what your plumbing - if Trump goes through with putting RFK Jr. in a position of power as far as the Department of Health and Human Services, he could do a LOT of damage as far as vaccines. Vaccines are not super profitable for pharma companies, despite what cranks think; they take a LOT of development for only a few uses. Vaccines are driven by public health requirements and a lot of places would shrug and say "ok, bet" if there isn't a guaranteed market for them.

The professional medical community will still have recommendations about when and how to vaccinate, but they won't have the force of law, and insurance will probably smell blood in the water and start kicking up a fuss about covering vaccines when they're not required. So then when doctors recommend them there'll be suspicion and pushback that they're just doing it for "kickbacks" even though the only doctor who would have gotten paid for vaccine is ironically Andrew Wakefield, the lying fuckshit, because his whole "vaccines cause autism" lie was to push his OWN, SPECIAL proprietary vaccines that wouldn't cause his made-up syndrome, because NO vaccines were causing it. May he roast somewhere warm when the devil comes for him.

This will not happen immediately, but. Because there will no doubt be anticipatory compliance on the part of drug companies and healthcare systems. I HIGHLY advise you get the fuck out there and get your Tdap updated (tetanus, diptheria and pertussis). Whooping cough is out there, and it is horrible for babies. If you are eligible for shingles vaccine and haven't done it, get that. Get your COVID vax if you haven't, there might not BE another one, at least not that's available in the US.

If you have kids, especially make sure THEY'RE up to date because their classmates might very well not be mandated to get them any more - state regulations will undoubtedly vary, but with the current composition of the Court, it will rule in favor of every possible exemption for antivaxxers as possible because the conservatives are all "fuck the weakest of us, I got mine fuck you." And expect idiocy like "pox parties" to spread (not like the average suburban parent can tell measles from rubella from chicken pox from hand foot and mouth by fuckin' looking at it, who knows what the christ they're going to be passing around). Measles is NOT just a "bit of a rash." Rubella is the world's leading preventable cause of birth defects. Chickenpox can result in scarring, encephalitis causing blindness or even death, and the risk of shingles later in life. I have a cousin who would be 57 this year who died as a toddler from hemophilus influenzae strain B meningitis, one of those "too many" childhood vaccines that were invented in the 1990s. Tell my aunt that's too many vaccines -oh, wait, you can't, she fucking killed herself out of grief her baby died.

tweens? get them the HPV vaccine if they haven't gotten it (given its associations with sex it'll probably be one of the first to go, but it prevents CANCER. who wants their child to get cervical cancer, or penile cancer, or throat cancer, or rectal cancer? IT PREVENTS CANCER. JUST DO IT.)

Similarly, if you have a child with any kind of immune issue that precludes vaccination, I would very much look into homeschooling, because bye-bye herd immunity.

If you have teenage kids, encourage them to update their Tdap and get the meningiococcal meningitis vaccine if they haven't been mandated to already by campus policy. Tetanus and meningitis aren't common, but they are frequently permanently life-altering when they're not fatal. We're talking months in the hospital. I'm old enough that I remember people fucking dying in college, and the panic that went around campus every time one of those breakouts happened in the state wondering if it would make its way to our campus.

Stay safe out there. I have no idea what this will do to our already teetering healthcare system but I don't think it'll be pretty. Everybody pray Trump pulls his usual scam and hangs RFK Jr. out to dry, because while the plutocrats consider regulations an unnecessary burden, they don't have a stake in creating a public health state of emergency when we already have a workforce not keeping up with demand, unlike Captain Convenient Brain Worm.

[breelandwalker]

Ahhh it's one of those weeks when we laugh to keep from screaming.

While recovering from my covid vaccine hangover and trying to track down the no-call-no-show contractors who were supposed to come and repair our broken furnace, I heard a dripping sound from the ceiling that turned out to be a roof leak in our attic. Probably from the big storm earlier this year, we had some bad wind shears come through and some of our neighbors lost shingles and siding, so I wouldn't be surprised. We don't have roof access to check, so it's bucket and insurance claim time.

Mind you, this is less than a month after husband's car finally went kaput and we had to get a new one, plus the kitties needing their annual checkup and flea treatments, and our home warranty is coming due (even though it takes some GALL to ask us to renew when they've been so useless with the current claim).

Catch me coping with this by screaming into a jar and then staying up late bingeing Penny Dreadful and making new batches of powder for the shop. Just like a witch, ain't it?

So suffice it to say, there's a few surprises heading for the shop in the coming months, and I'll have several new things on my table for the Yule weekend markets, if anyone wants to swing through Williamsburg or Richmond the weekend of the 21st. (And of course, regular shop orders are always welcome.)

Hope your December is going better than mine! 😅

[spacetimewithstuartgary]

New SpaceTime out Friday

SpaceTime 20250418 Series 28 Episode 47

Hubble helps determine Uranus' rotation rate with unprecedented precision

Astronomers using the Hubble Space Telescope have made new measurements of Uranus' rotation rate a thousand times more accurate than previous estimates.

Russian Soyuz arrives at space station

A new crew has arrived aboard the International Space Station with a Russian Soyuz capsule has successfully docking to the orbiting outpost.

The dangers of going to space

We all know that space is dangerous not just for satellites and spacecraft but also for people, so what are the dangers.

The Science Report

Study shows the shingles vaccine reduces the probability of dementia by 20 percent.

Scientists develop a meat flavour to make lab grown meat more meatier. 

Warning that Beak and Feather Disease is rampant in Australia’s Crimson Rosella population.

Skeptics guide to the spread of deep fakes using AI

SpaceTime covers the latest news in astronomy & space sciences.

The show is available every Monday, Wednesday and Friday through your favourite podcast download provider or from www.spacetimewithstuartgary.com

SpaceTime is also broadcast through the National Science Foundation on Science Zone Radio and on both i-heart Radio and Tune-In Radio.

SpaceTime daily news blog: http://spacetimewithstuartgary.tumblr.com/

SpaceTime facebook: www.facebook.com/spacetimewithstuartgary

SpaceTime Instagram @spacetimewithstuartgary

SpaceTime twitter feed @stuartgary

SpaceTime YouTube: @SpaceTimewithStuartGary

SpaceTime -- A brief history

SpaceTime is Australia’s most popular and respected astronomy and space science news program – averaging over two million downloads every year. We’re also number five in the United States.  The show reports on the latest stories and discoveries making news in astronomy, space flight, and science.  SpaceTime features weekly interviews with leading Australian scientists about their research.  The show began life in 1995 as ‘StarStuff’ on the Australian Broadcasting Corporation’s (ABC) NewsRadio network.  Award winning investigative reporter Stuart Gary created the program during more than fifteen years as NewsRadio’s evening anchor and Science Editor.  Gary’s always loved science. He studied astronomy at university and was invited to undertake a PHD in astrophysics, but instead focused on his career in journalism and radio broadcasting. Gary’s radio career stretches back some 34 years including 26 at the ABC. He worked as an announcer and music DJ in commercial radio, before becoming a journalist and eventually joining ABC News and Current Affairs. He was part of the team that set up ABC NewsRadio and became one of its first on air presenters. When asked to put his science background to use, Gary developed StarStuff which he wrote, produced and hosted, consistently achieving 9 per cent of the national Australian radio audience based on the ABC’s Nielsen ratings survey figures for the five major Australian metro markets: Sydney, Melbourne, Brisbane, Adelaide, and Perth. That compares to the ABC’s overall radio listenership of just 5.6 per cent. The StarStuff podcast was published on line by ABC Science -- achieving over 1.3 million downloads annually.  However, after some 20 years, the show finally wrapped up in December 2015 following ABC funding cuts, and a redirection of available finances to increase sports and horse racing coverage.  Rather than continue with the ABC, Gary resigned so that he could keep the show going independently.  StarStuff was rebranded as “SpaceTime”, with the first episode being broadcast in February 2016.  Over the years, SpaceTime has grown, more than doubling its former ABC audience numbers and expanding to include new segments such as the Science Report -- which provides a wrap of general science news, weekly skeptical science features, special reports looking at the latest computer and technology news, and Skywatch – which provides a monthly guide to the night skies. The show is published three times weekly (every Monday, Wednesday and Friday) and available from the United States National Science Foundation on Science Zone Radio, and through both i-heart Radio and Tune-In Radio.

[thoughtportal]

Oprah went on the air nationally in the 1980s, just as non-Christian faith healing and channeling the spirits of the dead and “harmonic convergence” and alternative medicine and all the rest of the New Age movement had scaled up. By the 1990s, there was a big, respectable, glamorous New Age counterestablishment. Marianne Williamson, one of the new superstar New Age preachers, popularized a “channeled” book of spiritual revelation, A Course in Miracles: The author, a Columbia University psychology professor who was anonymous until after her death in the 1980s, had claimed that its 1,333 pages were dictated to her by Jesus. Her basic idea was that physical existence is a collective illusion—”the dream.” Endorsed by Williamson, the book became a gigantic best-seller. Deepak Chopra had been a distinguished endocrinologist before he quit regular medicine in his 30s to become the “physician to the gods” in the Transcendental Meditation organization and in 1989 hung out his own shingle as wise man, author, lecturer, and marketer of dietary supplements.

Remember the satanic panic, the mass hysteria during the 1980s and early ’90s about satanists abusing and murdering children that resulted in the wrongful convictions of dozens of people who collectively spent hundreds of years incarcerated? Multiple Oprah episodes featured the celebrity “victims” who got that fantasy going.

Most of the best-known prophets and denominational leaders in the New Age realm owe their careers to Winfrey. Her man Eckhart Tolle, for instance, whose books The Power of Now and A New Earth sold millions of copies apiece, is a successful crusader against reason itself. “Thinking has become a disease,” he writes, to be supplanted by feeling “the inner energy field of your body.”

Oz has encouraged viewers to believe that vaccines cause autism and other illnesses—as did Winfrey on her show before him. In 2007, long after the fraudulent 1998 paper that launched the anti-vaccine movement had been discredited, she gave an Oprah episode over to the actress Jenny McCarthy, a public face of the movement.

[weirdlyvirtualumbra]

Congestive Heart Failure Treatment Devices Market Trends, Size, Share, Trends and Future Opportunities 2034 : SPER Market Research

Congestive heart failure treatment devices are medical devices for congestive heart failure (CHF), a condition in which the heart finds it difficult to pump blood efficiently, are made to strengthen heart function and enhance circulation in individuals with CHF.  These devices, which improve cardiac output and help control heart rhythms, include pacemakers, ventricular assist devices (VADs), implanted Cardioverter defibrillators (ICDs), and cardiac resynchronization treatment (CRT) devices.  Furthermore, remote monitoring devices help identify worsening symptoms early.  These tools are essential for treating CHF, lowering hospital stays, and enhancing patients' quality of life.  Device technology is always evolving to improve long-term results for CHF patients, decrease complications, and increase efficiency. 

According to SPER market research, ‘Global Congestive Heart Failure Treatment Devices Market Size- By Product - Regional Outlook, Competitive Strategies and Segment Forecast to 2033’ state that the Global Congestive Heart Failure Treatment Devices Market is predicted to reach 11 billion by 2034 with a CAGR of 6.98%. 

Drivers: 

Ventricular assist devices (VADs) and artificial heart pumps are two examples of technological developments in the treatment of heart failure that propel market expansion by enhancing patient outcomes and quality of life.  An aging population is leading to the surge in demand for these devices, which is further fueled by the rising prevalence of cardiovascular disorders, especially heart failure.  A key factor driving the sector is the ongoing development of heart failure treatment technologies, such as artificial heart pumps, ventricular assist devices (VADs), and minimally invasive alternatives.  Significant progress has been made in treatment approaches as a result of the rising incidence of heart failure, especially in proactive care and early intervention.   

Request a Free Sample Report: https://www.sperresearch.com/report-store/congestive-heart-failure-treatment-devices-market?sample=1  

Restraints: 

The market for congestive heart failure (CHF) therapy devices is confronted with various obstacles.  Particularly in poor nations, the high expense of implanted devices such as cardiac resynchronization treatment (CRT) and left ventricular assist devices (LVADs) restricts accessibility.  Long clinical trials and stringent regulatory permissions cause delays in product introductions.  Patients are also at serious risk from device-related problems such thrombosis, infections, and mechanical failures.  Market expansion is further hampered by low-income populations' lack of awareness and cost.  Another factor influencing acceptance is the lack of qualified medical personnel for device administration and insertion.  The broad use of CHF therapy devices is also being slowed by payment restrictions and changing healthcare regulations, which place a financial burden on both patients and providers. 

The global market for congestive heart failure therapy devices was led by North America.  An aging population, a high rate of heart disease, and sophisticated healthcare infrastructure are the main causes of this. Some significant market players are Abbott Laboratories, Biotronik SE & Co. KG, Boston Scientific Corporation, Koninkilijke Philips N.V. 

For More Information, refer to below link: –   

Congestive Heart Failure Treatment Devices Market Share 

  Related Reports:   

Arbovirus Testing Market Growth, Size, Trends Analysis - By Test Type, By Pathogen Detection, By Technology, By Application - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Shingles Vaccine Market Growth, Size, Trends Analysis - By Product, By Vaccine Type - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Follow Us –  

LinkedIn | Instagram | Facebook | Twitter  

Contact Us:  

Sara Lopes, Business Consultant — USA  

SPER Market Research  

enquiries@sperresearch.com  

+1–347–460–2899 

[nursingwriter]

Pharmaceutical Industries: Merck & Co., Inc. Order ID: Benchmarks in the Rise of Big Gov. 1901 -- 1981 International Pharmaceutical Industry The purpose of this work is to perform a general analysis of the international trends of the pharmaceutical industry in terms of global or local issues as well as the strategies of the leading company, Merck & Co., Inc. And to review the governmental policies toward the pharmaceutical industry. The Global Pharmaceutical Industry/Supply Chain: The pharmaceutical industry is global industry. Global pharmaceutical sales grew 10% at a constant rate in 2000 equaling $317.2 billion in total sales which was up from the 1999 amount of sales equaling $295.9 billion. Japan was the largest consumer in the 2000 pharmaceutical industry at 88% of total global consumption. Investor Concerns: The largest concerns of the investors in the industry are that: Government action will make it harder to get patents on products giving a rise to generic drugs. Medicare drug benefits could end up with legislation in Washington price-setting drugs. Open-ended class action market III. Trade in the Industry/Market & Network Merck Anticipates Full-Year 2005 Earnings Per Share Range of $2.42 to $2.52. Continued growth and development of newer franchises is planned by Merck in 2005 as well as extending the recent launches of ZETIA and VYTORIN, which have been a success thus far. New products are planned to be launched. Plans for the second half of 2005 are inclusive of plans by Merck in submission of three vaccines to the FDA for their approval. The vaccines which are planned for submittal are as follows: Rotavirus vaccine: "A 'highly contagious' virus that causes gastroenteritis and results in the hospitalization of nearly 50,000 children under age 5 each year in the United States." HPV vaccine: "This vaccine is engineered to reduce human papillomavirus infection and complications of cervical dancer that kills more women than any other disease each year. Shingles Vaccine: A Vaccine that reduces the pain that is part of the condition of shingles and is suffered by 1 million American adults per year. Merck and Co., Inc. is a "global research-driven pharmaceutical company that focuses on discovering, developing, manufacturing and marketing a broad range of innovative products to improve human health both directly as well as through its joint ventures. Merck & Company, Inc. announced on September 30, 2004 "a worldwide withdrawal of VIOXX (rofecoxib) its arthritis and acute pain medication." According to the report the decision is 'effective immediately' and is 'based on a new, three-year data from a prospective, randomized placebo-controlled clinical trial, the APPROVe (Ademonatous Polyp Prevention on VIOXX) trial." The stated adverse effects of stroke or heart attack have been cited to be caused by VIOXX in certain patients. Merck is presently reimbursing all customers for unused prescriptions which have been filled by the patient. "Recently announced by Merck on November 23, 2004 is that: "the quarterly dividend $0.38 per share on the company's common stock for the first quarter of 2005. The dividend is payable January 3, 2005 to stockholders of records at the close of business on December 3, 2004. Growth in the ZETIA and VYTORIN franchises are expected to continue. T There are currently several candidates in Phase III that Merck plans to file in 2005 as well as Type 2 diabetes treatment and three vaccines. The fourth-quarter 2004 EPS anticipation is stated to be $0.48 to $0.53, which includes the impact of approximately "$700 to $750 million foregone sales of VIOXX. The result is anticipation by Merck for EPS guidance (2004 full-year) of $2.59 to $2.64. These amounts include withdrawal impact and next years negative affects of the DPS by $0.50 to $0.55." Merck & Co., Inc. announced in a recent report that they had made submission to the U.S. Food and Drug Administration (FDA) PROQUAD, which is a vaccine for children. The composition of the vaccine is a cocktail like mixture of the chickenpox, measles, mumps and rubella vaccine. Also expected by Merck for submission is 'muraglitazar' which is the "first-in-class 'dual PPAR agonist for Type 2 diabetes treatment in collaboration with Bristol-Myers Squibb."(Merck & Co, Inc. 2004) In a December 7, 2004 Press Release the announcement made by the Board of Directors of Merck & Co., Inc. that a "Special Board Committee to review the company's actions prior to Merck's voluntary withdrawal of VIOXX, to act for the Board in responding to shareholder litigation matter related to the withdrawal of VIOXX and to advise the Board with respect to any action that should be taken as a result of the review." IV. Competitive Countries: Competitive Countries in the Pharmaceutical Industry are with the United States as the top competititor with 48.20% of global sales and a 2000 sales figure of $152.9 billion and a 14% year-over-year growth. Europe follows the United States with 23.7% of global sales for the sum of .3 billion and an 8% year-over-year growth. Japan is the third top competitor with 16.2% of global sales in the amount of $51.5 billion and a 3% year-over- year growth followed by Latin America who claimed 6% of global sales for the sales figure of $18.9 billion and 9% year-over year growth. Asia, Africa and Australia follow Latin America with 5.9% of global sales equaling $18.7 billion and a 1-% year-over-year growth. The total sales for the pharmaceutical industry in 2000 were $317.20 billion with a 10% year-over-year growth. Conclusion: The pharmaceutical industry is an industry that will continue to be in demand especially due to the need for vaccines due to re-emergent diseases in the form of Tuberculosis and others which have emerged again that had been deemed extinct. Bibliography: "Merck Board Appoints Special Committee to Review VIOXX Withdrawal" 2004 Dec 2 Whitehouse Stations, N.J. available at: http://www.merck.com/news room/press_releases/corporate/2004_1207.html The global pharmaceutical market in 2000 - North America sets the pace (nd) available at: http://www.ims-global.com/insight/news_story/0103 / news_ story _010 314.htm Merck Announces Voluntary Worldwide Withdrawal of Vioxx 2004 Sep 30 available at: http://www.vioxx.com/rofecoxib/vioxx/hcp/hcp_notification_physicians.jsp Paraphrased Read the full article

[mitalipingale]

https://www.pittsburghtribune.org/read-blog/116310_shingles-vaccine-market-share-overview-competitive-analysis-and-forecast-2031.html

The Shingles Vaccine Market in 2023 is US$ 3.99 billion, and is expected to reach US$ 8.63 billion by 2031 at a CAGR of 10.10%.

[nursingassistantsrock]

The Zoster Vaccine

The Zoster Vaccine: Prevention of Herpes Zoster and Post-herpetic Neuralgia The Zoster vaccine (marketed as Shingrix and formerly as Zostavax) is a vaccine designed to prevent herpes zoster, commonly known as shingles, and its complications. Shingles is caused by the reactivation of the varicella-zoster virus (VZV), the same virus responsible for chickenpox (Cohen et al., 2023). Mechanism of…

[spaciousreasoning]

Seeing Our Way Forward

The weather app last night showed snow a possibility for today, with the low this morning at 31 degrees and the high only reaching 39. Even though a little snowflake showed up on the app, no precipitation fell during the daytime. Nevertheless, a little something wet was falling from the skies after the sun went down.

The morning blood sugar popped up to 181. I checked it right after the eye drops were administered, so the high number is probably due to the pasta dinner last night and the Cheetos binge later.

After enjoying our coffee and playing the brain games, we had a piece of toast before heading off for Nancy’s eye appointment for the corneal transplant consultation. We bundled up to be out early to make it. I went along in case they had to dilate her eyes, which would mean she couldn’t drive.

The appointment did not yield any good news. The shingles is still active in her eye, so the doctor is not willing to do any procedure right now. Nancy was prescribed some drops and pills that will help alleviate treat the illness. She’s also supposed to get another shingles vaccine. The next appointment is in two weeks to check the pressure in her eye.

While she was in with the doctor, I spent time reading some of the magazines on the table in the waiting area. There were copies of The New Yorker, Sports Illustrated, Science, a home decor publication, a rural life magazine, and the Oregon Leaf, one of a family of magazines practicing “Cannabis journalism.” Guess I’ve got a new one for the “10th Muse” section of the next BudZine.

Speaking of which, I will be publishing BZ No. 32, Winter 2025, in the next few days. I’m trying to get all the HTML and CSS figured out ahead of time so things won’t get screwed up during the transition. I’ve already started on No. 33. I’ve cleared the way for the content and added a new quote about the free press.

When Nancy’s doctor visit was done, we drove up Coburg Road to Market of Choice to get some bacon. Then we came home and fried up the leftover roasted potatoes, a couple of eggs, and put the bacon in the oven. We made some plain toast, and had brunch.

I’ve been getting lots of spam in the morning email lately. Most of it is sex-related, and most of it is caught by the email program. The spam comes and goes in waves.

One of Nancy’s prescriptions from this morning became available at the Target/CVS, so we drove over after lunch for her to pick it up. The eye drops she’s going to use won’t be available until tomorrow.

After that we went to Costco to fill up the tank. It was just below half, but with the insanity created by the new Administration, we figured we would go ahead in case the price was going up. Turned out to be the same it was last time we filled up, $3.18 per gallon.

About 5:30 p.m. I heated up a bit of the chicken Alfredo leftover from last night and had that for my dinner before taking off for the Tuesday night men’s recovery meeting. I picked up Henry and we had a room full of fellows, including the MAGAt, who wore a hat with the Chief Felon’s face on it. The reading was about “the only requirement for membership is a desire to stop using.” Even if you’re still using, you are still welcome to the fellowship. We want you to stick around until it works for you.

Nancy ate a few miscellaneous things for her own dinner while I was away. Then we streamed the Monday night Colbert, with guests Lin-Manuel Miranda and Audra McDonald, and the third episode in “The Gone,” and one of the missing young people turned up dead right at the end.

There is supposed to be a bit of snow overnight, and tomorrow’s low is again 31 degrees, with a high perhaps reaching 40. The snow might continue into the morning, but then the rain should arrive and simply make everything wet.

[decentralvaccine]

Shingles Vaccine To Reach $12.9B By 2034

Shingles vaccine market size was valued at USD 4.9 billion in 2024 and is projected to grow at a robust CAGR of 10.1% from 2025 to 2034. Key factors driving this growth include the increasing aging population, improved reimbursement frameworks, and heightened awareness about shingles prevention and complications.

[businessconsultantsposts]

Private Vaccinations: A Gateway to Personalized Immunization

Vaccinations are a cornerstone of preventive healthcare, offering protection against various infectious diseases. While public vaccination programs play a vital role in achieving widespread immunity, private vaccinations have emerged as a complementary option for individuals seeking personalized and convenient immunization solutions. These services cater to diverse needs, ensuring accessibility, choice, and enhanced healthcare experiences.

What Are Private Vaccinations?

Private vaccinations refer to immunization services provided by private healthcare providers outside government-funded programs. These services often include vaccines not covered under public schedules or those that cater to specific demographic or travel-related needs. Delivered in clinics, hospitals, or dedicated immunization centers, private vaccinations prioritize flexibility and personalization.

Advantages of Private Vaccinations

Private vaccinations offer several benefits that make them an appealing option for individuals and families:

Broader Vaccine Choices: Private providers often stock vaccines beyond the standard public health schedule, such as travel vaccines, newer formulations, or those for rare conditions.

Convenience and Accessibility: Private vaccination clinics frequently offer extended hours, shorter waiting times, and the ability to schedule appointments at the patient’s convenience, reducing barriers to immunization.

Customized Services: Tailored recommendations based on individual health needs, lifestyle, or travel plans ensure a more personalized approach to immunization.

Timely Availability: In cases where public supplies are delayed or limited, private vaccinations provide an alternative, ensuring timely protection against diseases.

Enhanced Privacy and Comfort: Private clinics often provide a more comfortable and confidential environment, appealing to individuals who prefer discreet healthcare services.

Types of Vaccines Offered Privately

Private vaccination services encompass a wide range of immunizations, including:

Travel Vaccines: Vaccinations against diseases like yellow fever, typhoid, hepatitis A, and Japanese encephalitis are essential for international travelers.

Optional Vaccines for Children: While national programs cover core vaccines, parents may opt for additional protections such as meningococcal or rotavirus vaccines through private providers.

Adult Immunizations: Vaccines like shingles, human papillomavirus (HPV), and pneumococcal disease cater to adults seeking protection from age-specific or lifestyle-related risks.

Seasonal Vaccines: Private flu vaccines are popular for those who miss public campaigns or prefer newer vaccine formulations.

Considerations When Choosing Private Vaccinations

While private vaccinations provide numerous benefits, individuals should consider a few factors:

Cost: Unlike government-funded programs, private vaccinations involve out-of-pocket expenses. It’s important to assess affordability and insurance coverage.

Credibility of Providers: Ensure the clinic or provider is reputable and employs qualified healthcare professionals for administering vaccines.

Compatibility with Public Programs: Verify whether the chosen vaccine aligns with the national immunization schedule and is recognized by local health authorities.

Potential Side Effects: As with any medical intervention, vaccines may have side effects. Consulting a healthcare provider can help manage expectations and ensure safety.

The Role of Private Vaccinations in Public Health

Private vaccinations complement public health initiatives by filling gaps in immunization coverage, addressing specific needs, and alleviating pressure on public systems. They also play a crucial role in driving innovation and introducing new vaccines to the market.

Conclusion

Private vaccinations offer a valuable option for individuals seeking tailored, convenient, and comprehensive immunization services. By bridging gaps and expanding access to a wider range of vaccines, they empower individuals to take proactive control of their health. As the demand for personalized healthcare grows, private vaccinations will continue to be a vital component of modern preventive medicine.